Praziquantel is the drug the world relies on to treat schistosomiasis, a parasitic infection carried by freshwater snails that affects well over 200 million people. It is cheap, generally well tolerated, and very effective against adult worms. It has one important weakness: it works poorly against the immature worms present in the first several weeks after infection. This article explains what is known about that weakness, how it shapes the illness travelers develop after a freshwater exposure (acute schistosomiasis, or Katayama syndrome), and why physicians commonly give a second course of praziquantel 6 to 12 weeks after the last exposure rather than treating once and stopping.
How the parasite develops, and where praziquantel acts
Infection begins when free-swimming larvae called cercariae, released by snails, penetrate intact skin during swimming, wading or washing. Within hours they shed their tails and become schistosomula. Over the following days they enter the bloodstream and pass through the lungs. Over several weeks they mature in the veins of the liver, where males and females pair. The pairs then migrate to the veins of the intestine (Schistosoma mansoni, S. japonicum) or the bladder (S. haematobium) and begin laying eggs. Egg-laying typically starts around five to seven weeks after infection for S. mansoni and somewhat later for S. haematobium. The eggs, not the worms themselves, cause most of the disease, because the body walls them off with inflammation and scarring.
Praziquantel was developed in the 1970s by German pharmaceutical chemists. It is a wholly synthetic compound, not one drawn from a plant or soil organism. Within seconds of exposure, susceptible worms contract violently, take up calcium, and develop blisters and damage on their outer surface, the tegument. For decades the precise molecular target was unknown. Work from Jonathan Marchant's laboratory at the Medical College of Wisconsin, published around 2019 to 2021 in journals including the Journal of Biological Chemistry, identified a parasite ion channel of the TRPM family that praziquantel opens. Independent genetic mapping of drug-resistant laboratory worms by Timothy Anderson's group at Texas Biomedical Research Institute, reported in Nature Communications in 2021, pointed to the same channel. This is now the leading explanation of how the drug works, though research continues.
The body's own defenses also matter. Experiments in mice during the 1980s, including work by Brindley and Sher in the Journal of Immunology, showed that praziquantel cleared worms far less effectively in animals lacking antibodies. The drug appears to damage the worm's surface, exposing hidden antigens to the immune system, which then finishes the work. The host's immune system and the medicine work together: the drug opens the door and the body's defenses complete the cure.
The juvenile gap: what the evidence shows
The stage-specific weakness of praziquantel is among the better-established facts in parasitology. Most of the detailed evidence, however, comes from laboratory and animal studies rather than controlled human trials.
- Animal and laboratory studies. A 1985 study by Xiao, Catto and Webster in the Journal of Infectious Diseases and a 1986 study by Sabah and colleagues in Experimental Parasitology treated mice at different times after infection with S. mansoni. Both found a consistent pattern. Very early skin-stage larvae show some susceptibility. Sensitivity then falls to its lowest point roughly three to four weeks after infection and recovers as worms reach adulthood at around six to seven weeks. Later work by Pica-Mattoccia and Cioli in the International Journal for Parasitology (2004) confirmed that juvenile worms around four weeks of age are largely refractory. It also found that adult females are less sensitive than adult males.
- Human evidence. Controlled trials timed to the juvenile stage would be neither practical nor ethical, so the human evidence is observational. It is nonetheless consistent with the animal data. Travelers treated within a few weeks of exposure often later show persistent eggs, rising antibodies, or recurrent symptoms. A French series by Grandière-Pérez and colleagues in the American Journal of Tropical Medicine and Hygiene (2006) followed travelers exposed to S. haematobium who were treated during the incubation or acute phase. Treatment failures were common enough that the authors supported routine retreatment.
Why juveniles survive is less settled. Proposed explanations include differences in the immature tegument and in calcium handling, possible differences in expression of the drug target, higher activity of drug-export pumps (P-glycoprotein-type transporters) in young worms, and a weaker immune contribution against stages that have not yet displayed the relevant surface antigens. These explanations are supported by laboratory data of varying strength. None has been proven to be the sole cause.
The practical consequence is straightforward. A single dose of praziquantel given in the first month or so after infection may relieve nothing and cure nothing, because the worms it needs to kill are not yet vulnerable. For the same reason, taking praziquantel before or immediately after swimming does not protect against infection and is not recommended.
Katayama syndrome: acute schistosomiasis in travelers
People who grow up in endemic areas are usually infected repeatedly from childhood and rarely develop a dramatic acute illness. First-time visitors are different. Missionaries, volunteers, aid workers, adventure travelers and expatriate families often have no prior immunity. Many develop a feverish illness known as Katayama syndrome or Katayama fever, named after a district in Japan where S. japonicum was once common. Well-documented clusters have followed swimming in Lake Malawi, Lake Victoria and Lake Tanganyika, rafting in East African rivers, and trekking in Mali's Dogon country. An outbreak traced to a river in Corsica in the 2010s showed that transmission can occasionally occur even in southern Europe.
The illness usually begins between two and eight weeks after exposure, often around three to six weeks. It is thought to reflect a strong immune and immune-complex reaction to maturing worms and the first eggs. Typical features include:
- Fever, often with sweats, fatigue and headache
- Dry cough and sometimes wheeze, with patchy changes on chest imaging
- Itchy rash or hives, and swelling of the face or limbs
- Muscle and joint aches, abdominal pain or diarrhea
- A marked rise in eosinophils, a type of white blood cell, on blood testing
A series of 46 patients from the Institute of Tropical Medicine in Antwerp, reported by Bottieau and colleagues in Medicine (2006), described this picture in detail. It also documented less common but serious complications, including involvement of the heart and nervous system. A 2007 review by Ross and colleagues in The Lancet Infectious Diseases remains a standard summary.
Diagnosis is often difficult early on. Eggs may not yet appear in stool or urine, and antibody tests can be negative for the first several weeks. A history of freshwater contact therefore carries a great deal of weight. Travelers who mention the lake swim or river crossing to their physician make the diagnosis far easier.
Why treatment is timed, and repeated, the way it is
The stage-specific biology explains the common clinical approach in specialist travel medicine. In acute schistosomiasis, the worms causing symptoms are often still juveniles. Praziquantel given at that point may kill relatively few of them. Some patients also experience a temporary worsening of fever and inflammation after the first dose, probably because dying parasites release antigens. For this reason, clinicians frequently use corticosteroids to control the inflammatory reaction in the acute phase. This practice rests on case series and expert experience rather than randomized trials, and physicians should explain that to patients.
Many specialists give a first course of praziquantel at diagnosis, often alongside steroids. They then repeat it once the surviving worms have matured and become susceptible. In practice this means:
- A second course roughly 6 to 12 weeks after the last freshwater exposure, when surviving juveniles should have reached the vulnerable adult stage.
- For travelers without symptoms who know they were exposed, a common approach is to wait until at least 6 to 12 weeks have passed before testing and treating. Earlier treatment risks missing the worms entirely, and earlier blood tests risk false reassurance.
- Follow-up testing afterward, recognizing that antibodies can remain positive for years after successful cure. A positive antibody test alone therefore does not prove ongoing infection.
Standard doses differ by species. Commonly used regimens are 40 mg/kg per day for S. mansoni and S. haematobium, and 60 mg/kg per day in divided doses for S. japonicum and S. mekongi. The right regimen for any individual is a decision for the treating physician. Guidance varies somewhat between national bodies, and this article is not a substitute for that individual judgment.
Filling the gap: research directions
Because praziquantel is essentially the only drug in wide use, researchers have looked for agents that kill juvenile worms. The most studied are the artemisinin derivatives, compounds derived from sweet wormwood (Artemisia annua), a plant used in traditional Chinese medicine for centuries. Its usefulness against parasites is a good example of the remarkable resources the natural world holds. Work led by Xiao Shuhua and others in China showed that artemether and artesunate are active mainly against juvenile schistosomes, almost the mirror image of praziquantel. Some trials and a 2012 meta-analysis in PLoS ONE suggest that combining an artemisinin with praziquantel may improve cure rates over praziquantel alone. The evidence is mixed, however. These drugs are not approved for treating schistosomiasis in the United States or Europe, and their wider use is restrained by the need to protect them as frontline malaria treatments.
Other progress is more immediate. Praziquantel is a mixture of two mirror-image molecules, and the active one is the R-form. A child-friendly formulation of the active form, arpraziquantel, received a positive scientific opinion from the European Medicines Agency in 2023 for children aged three months to six years. This age group had long been underserved.
Pregnancy, children and informed decisions
For many years pregnant women were excluded from treatment campaigns, leaving both mother and unborn child exposed to an infection associated with anemia and poorer health. Randomized trials have since provided reassurance. One was conducted by Ndibazza and colleagues in Uganda (Clinical Infectious Diseases, 2010), and another by Olveda and colleagues in the Philippines (The Lancet Infectious Diseases, 2016). Neither found evidence that praziquantel harmed pregnancy outcomes, though neither showed clear benefit to birth weight. The World Health Organization supports treating infected pregnant women after the first trimester. Every expectant mother deserves care that protects both of the lives she carries, and that decision belongs with her and her doctor, based on the actual evidence.
Families planning travel can prepare sensibly. They can learn which waters carry risk, avoid swimming or wading in fresh water in endemic regions, keep a record of exposure dates, and share them with their physician on return. Patients have every right to ask why a second dose is proposed, what tests mean, and what the alternatives are. Informed consent rests on understanding, and the biology here is clear enough to explain.
Key takeaway: Praziquantel reliably kills adult schistosomes but largely spares the juvenile worms present in the first weeks after infection, which is why physicians time treatment carefully and commonly repeat it 6 to 12 weeks after the last freshwater exposure.